Trial Profile
A feasibility study of capecitabine plus oxaliplatin (CapeOX) and S-1 plus oxaliplatin (SOX) for unresectable advanced or reccurent gastric cancer
Status:
Not yet recruiting
Phase of Trial:
Phase IV
Latest Information Update: 09 Oct 2014
Price :
$35
*
At a glance
- Drugs Gimeracil/oteracil/tegafur (Primary) ; Capecitabine; Oxaliplatin
- Indications Gastric cancer
- Focus Adverse reactions
- 09 Oct 2014 New trial record